Compare QNST & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QNST | IOVA |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.0M | 2.1B |
| IPO Year | 2009 | 2008 |
| Metric | QNST | IOVA |
|---|---|---|
| Price | $12.16 | $4.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $24.75 | $9.11 |
| AVG Volume (30 Days) | 828.8K | ★ 15.8M |
| Earning Date | 05-07-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $282,140,000.00 | N/A |
| Revenue This Year | $18.59 | $49.14 |
| Revenue Next Year | $14.96 | $51.69 |
| P/E Ratio | $12.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.29 | $1.64 |
| 52 Week High | $19.53 | $5.63 |
| Indicator | QNST | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 54.58 |
| Support Level | $10.79 | $1.99 |
| Resistance Level | $12.62 | $4.34 |
| Average True Range (ATR) | 0.46 | 0.48 |
| MACD | 0.16 | 0.06 |
| Stochastic Oscillator | 75.41 | 42.91 |
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia. Geographically, it operates in United States and Internationally, of which maximum revenue is derived from United States.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.